Literature DB >> 32133141

Meropenem, rifampicin and gentamicin combination therapy in a patient with complicated urinary tract infection caused by extreme drug-resistant P. aeruginosa.

Aslınur Albayrak1, Dolunay Merve Fakioğlu2, Esin Şenol3.   

Abstract

In this article, we report a case of a 25-year-old male patient who was under follow-up for nephrolithiasis and repeated urological interventions. His last operation was carried out 9 months ago for insertion of a double-J catheter. Pseudomonas aeruginosa, which is susceptible to only colistin treatment, was detected in the urine culture. Before the removal of the double-J catheter, colistin and ceftazidime antibiotics were started to prevent the risk of bloodstream infection. However, the treatment was stopped urgently due to signs of nephrotoxicity. His treatment was restarted with colistin 300 mg once as the initial loading dose, followed by 150 mg/day. However, this time, colistin neurotoxicity has developed and the treatment was again stopped. Meropenem 6 g/day, gentamicin 2 mg/kg and rifampicin 300 mg were prescribed. Negative urine culture was achieved on the fifth day of treatment. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drug administration (others); infection control; infectious diseases; pharmacology; urology

Year:  2019        PMID: 32133141      PMCID: PMC7043256          DOI: 10.1136/ejhpharm-2019-001873

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  8 in total

1.  Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.

Authors:  G L Drusano; Weiguo Liu; Christine Fregeau; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

2.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Rajbharan Yadav; Jürgen B Bulitta; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.

Authors:  Warren E Rose; Peter T Poppens
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

Review 5.  Colistin: an antibiotic and its role in multiresistant Gram-negative infections.

Authors:  Tonny Loho; Anti Dharmayanti
Journal:  Acta Med Indones       Date:  2015-04

6.  Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.

Authors:  Karri A Bauer; Jessica E West; James M O'Brien; Debra A Goff
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

Review 7.  Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

Review 8.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.